Following the introduction to HyQvia® and the discussion on the onboarding of new patients in the previous two episodes, this episode focuses on the specific characteristics of HyQvia®.

In this podcast episode, nursing specialist Alina Ladariu discusses her experiences with HyQvia® during the onboarding process of new patients.

This podcast episode dives into the topic of subcutaneous immunoglobulins (SCIG). More precisely, we discuss the application of HyQvia®, an innovative medication for the subcutaneous administration of immunoglobulins facilitated by hyaluronidase.

HyQvia® is an immunoglobulin solution for subcutaneous application. Facilitated by recombinant human protein hyaluronidase, immunoglobulin absorption and bioavailability will be improved, allowing for the application of high immunoglobulin volumes. Thus, HyQvia® can be applied once or twice monthly at home.

Cuvitru® is a 20% immunoglobulin solution for subcutaneous application at home.

Kiovig® is a 10 % immunoglobulin solution that is applied intravenously (IVIG). Having been on the Swiss market since 2006 Kiovig® has been widely used for children and adults in indications such as primary immunodeficiency (PID), secondary immunodeficiency (SID) and rare autoimmune diseases (RAID).